Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Skye Bioscience Inc (OP: SKYE )

1.780 +0.050 (+2.89%)
Streaming Delayed Price Updated: 2:13 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Skye Bioscience Inc

< Previous 1 2 Next >
Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial... 
Via Benzinga
Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma
Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has... 
Via Benzinga
Easy On The Eyes — This Company Reports Using a Unique Synthetic Cannabinoid Derivative To Treat Glaucoma
Modern cannabis research reportedly began with Israeli scientists Raphael Mechoulam and Yechiel Gaoni who, in 1964, isolated and identified tetrahydrocannabinol (THC).   Mechoulam later also elucidated... 
Via Benzinga
Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer
Skye Bioscience, Inc. (OTCQB: SKYE) , a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing... 
Via Benzinga
Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details
Skye Bioscience, Inc. (OTCQB: SKYE) and Emerald Health Therapeutics, Inc. 
Via Benzinga
Skye Bioscience Targets Unmet Needs Of Glaucoma Through Cannabinoids
Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this artic... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma
Skye Bioscience, Inc. (OTCQB:SKYE) has entered into... 
Via Benzinga
Cannabis Movers & Shakers: Skye Bioscience, The Flowr Corp, Charlotte's Web, Rapid Dose Therapeutics
Skye Bioscience Announces Board Additions & Promotions CBD-focused biopharmaceutical company Skye Bioscience, Inc. 
Via Benzinga
These OTC Securities Had the Most Trading Activity in June
Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Watch CV Sciences & Lyphe Group On The Benzinga Cannabis Hour
Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday’s show, hosts Elliot Lane... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.